WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2007008080) OPTICAL IMAGING CONTRAST AGENTS
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2007/008080    International Application No.:    PCT/NO2006/000264
Publication Date: 18.01.2007 International Filing Date: 10.07.2006
Chapter 2 Demand Filed:    29.10.2007    
IPC:
A61K 49/00 (2006.01)
Applicants: GE HEALTHCARE AS [NO/NO]; Postboks 4220 Nydalen, Nycoveien 1-2, N-0401 Oslo (NO) (For All Designated States Except US).
JOHANNESEN, Edvin, Wilhelm, M. [NO/NO]; (NO) (For US Only)
Inventors: JOHANNESEN, Edvin, Wilhelm, M.; (NO)
Agent: WULFF, Marianne, Weiby; Postboks 4220 Nydalen, Nycoveien 1-2, N-0401 Oslo (NO).
CANNING, Lewis, Reuben; GE Healthcare Limited, Amersham Place, Little Chalfont, Buckinghamshire HP7 9NA (GB)
Priority Data:
20053354 11.07.2005 NO
Title (EN) OPTICAL IMAGING CONTRAST AGENTS
(FR) AGENTS DE CONTRASTE POUR IMAGERIE OPTIQUE
Abstract: front page image
(EN)The invention relates to optical imaging contrast agents. More specifically the invention relates to optical imaging activatable contrast agent for use in diagnosis and for monitoring the effect of treatment. The contrast agent employs a combined targeting and activation approach and comprises a target binding ligand (V), an enzyme cleavable group (E), a fluorophore (D) and a quencher agent (Q) covalently linked in one molecule.
(FR)L'invention concerne des agents de contraste pour imagerie optique. D'une manière plus spécifique, l'invention concerne un agent de contraste activable pour imagerie optique destiné à être dans le diagnostic et la surveillance de l'effet de traitement. L'agent de contraste utilise un ciblage et une activation combinés et comprend un ligand de liaison à la cible (V), un groupe clivable par enzyme (E), un fluorophore (D) et un agent d'extinction (Q) liés par covalence dans une molécule.
Designated States: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)